From July 1, 2022 to September 30, 2022, the company has repurchased 1,716,300 shares, representing 0.18% for CNY 19.79 million. With this, the company has completed the repurchase of 1,716,300 shares, representing 0.18% for CNY 19.79 million under the buyback announced on June 10, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.08 CNY | -1.31% | -2.27% | -0.66% |
27/05 | ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets | MT |
07/05 | China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.66% | 158.8Cr | |
+50.54% | 78TCr | |
-7.13% | 35TCr | |
+18.81% | 33TCr | |
+7.50% | 29TCr | |
+16.91% | 25TCr | |
+0.53% | 22TCr | |
+11.06% | 22TCr | |
+3.72% | 16TCr | |
-3.91% | 16TCr |
- Stock Market
- Equities
- 603567 Stock
- News Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.